Previous Close | 0.5125 |
Open | 0.5074 |
Bid | 0.5087 x 1300 |
Ask | 0.5000 x 2200 |
Day's Range | 0.4900 - 0.5150 |
52 Week Range | 0.4000 - 2.8700 |
Volume | |
Avg. Volume | 55,968 |
Market Cap | 17.03M |
Beta (5Y Monthly) | 2.63 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.4700 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.83 |
Subscribe to Yahoo Finance Plus to view Fair Value for UNCY
LOS ALTOS, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two upcoming investor conferences in December 2023. Noble Capital Markets 19th Annual Emerging Growth Equity Conference (NobleCon)Presentation: Monday, December 4, 2023 at 3:30 pm ET Boca Rat
Unicycive Therapeutics ( NASDAQ:UNCY ) Third Quarter 2023 Results Key Financial Results Net loss: US$4.41m (loss...
Reached Alignment with the FDA on the Data Package Requirements to File NDA for oxylanthanum carbonate (OLC) OLC Pivotal Clinical Trial Expected to Initiate Before Year End LOS ALTOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2023, and provided a bus